**Haemoglobin Variability in Patients with Chronic Kidney Disease Stage 5 under Haemodialysis.**

Elmetwally L. Elshahawy, Atef A. Ibrahim, Mohammed E. Salem, Sameh B. Hannalla And Medhat A. Khalil

Internal Medicine department, Faculty of Medicine, Benha University, Qalubia, Egypt

[medhatkhalil2010@yahoo.com](mailto:medhatkhalil2010@yahoo.com)**.**

**Abstract: Background:** Hemoglobin variability is the fluctuation of hemoglobin above or below the target range over time. Haemoglobin variability had found to be a frequent finding in haemodialysis patients treated with rHuEPO. **Methods:** In this study, we studied the Contributors and Consequences of Haemoglobin Variability in 60 Patients who are stage 5 CKD under haemodialysis in haemodialysis unit at Benha University Hospital who were prospectively studied over successive six months period**. Results:** Iron treatment, iron deficiency, secondary hyperparathyroidism, HCV virus infection, interfering drugs with haematopoiesis e.g., ACEI or ARBs and male gender were significant contributing factors for haemoglobin variability. Other infections e.g., UTI, chest infections, gum and catheter related infections might play a role as a contributing factor for haemoglobin variability. Cardiac diseases were significant consequences of haemoglobin variability. Weakness, fatigue and autonomic dysfunction might be consequences of haemoglobin variability. **Conclusions:** We have found haemoglobin variability to be a frequent finding in haemodialysis patients treated with rHuEPO. We need to do every effort to minimize haemoglobin variability in haemodialysis patients by reducing incidence of contributing factors of haemoglobin variability.

[Elmetwally L. Elshahawy, Atef A. Ibrahim, Mohammed E. Salem, Sameh B. Hannalla And Medhat A. Khalil. **Haemoglobin Variability in Patients with Chronic Kidney Disease Stage 5 under Haemodialysis.** *Nat Sci* 2015;13(10):98-106]. (ISSN: 1545-0740). <http://www.sciencepub.net/nature>. 13

**Key words:** Haemoglobin variability in haemodialysis patients.

**1. Introduction**

Hemoglobin variability is the fluctuation of hemoglobin above or below the target range over time. Hence, hemoglobin variability is the extent to which multiple measured hemoglobin values differ from each other within a given time span, whereas the calculated mean of all hemoglobin levels may still remain within the target range **(1).**

**Factors Affecting Hemoglobin Variability:**

**Drug-Related Factors**

Drug-related factors such as differences in pharmacokinetic and bioavailability parameters among ESA and different routes of administration (intravenous *versus* subcutaneous (**2)**, may affect hemoglobin stability in patients with CKD.

**Patient-Related Factors**

Hemoglobin levels vary by age, gender, and race. In general, lower hemoglobin levels have been observed with increasing age, in women compared with men, and in black patients compared with white patients **(3).**

**Factors Related to Medical Care and Reimbursement Policies**

Hemoglobin variability is also affected by anemia management practice patterns, which in turn are influenced by clinical practice guidelines, treatment protocols, and, in particular, reimbursement policies (**4**).

Additional reasons for hemoglobin variability include acute or chronic comorbidities(**5)**; alteration in iron stores**(6);** infection or inflammation**(7);** blood loss or transfusion**(8);** dialysis treatment features such as dialysis adequacy**(9**) or water quality**(10);** stage of CKD and residual renal function**(11)**; level of parathyroid hormone**(12);** vitamin and mineral status such as vitamin D, B12, or folate deficiencies (**13);** and seasonal effects**(10)**.Hemoglobin variability is more prominent in patients who are younger, have lower albumin or higher serum ferritin levels, or have changes in appetite**(14),** possibly related to alterations in nutritional or inflammatory status**(15),** and higher mean corpuscular hemoglobin (**16),** Iron supplementation strategies, for example, intravenous iron maintenance *versus* repletion, may cause different patterns of variations in hemoglobin level.

**Consequences of Hemoglobin Variability**

In maintenance dialysis patients, hemoglobin variability seems to be associated with increased risk for death according to at least two studies **(17).**

In addition to associations of blood hemoglobin with mortality and hospitalizations in the CKD population, anemia is associated with fatigue, weakness, shortness of breath, and a decreased health-related quality of life (**18).** Furthermore, hemoglobin overshoot may be associated with various safety concerns, including the development of elevated BP with risk for hypertensive encephalopathy **(19**), iron deficiency **(20)**, high platelet count **(21)**, thrombotic events **(22),** and accelerated left ventricular dysfunction and hypertrophy (**23**).

**2. Patients and Methods**

60 Patients who are stage 5 CKD under haemodialysis in haemodialysis unit at Benha University Hospital were prospectively studied over successive six months period from July 2014 to January 2015.

**Inclusioncriteria**

* Male and female patients.
* Age more than 17 years.
* Patients who are stage 5 CKD under haemodialysis

**Exclusion criteria**

* Age less than 17 years.
* Patients with acute kidney injury.
* Patients with history of bleeding and bleeding tendencies.
* Patients with TB.
* Patients with concurrent haematological disorders (e.g., sickle cell anemia).
* Patients receiving cancer chemotherapeutic agents and HIV medications.

All of them were subjected to the following after taking their informed written consents:

* Complete history and physical examination.

**History of :**

* **Factors related to patient demographics:**

Age/ yr.

Causes and duration of ESRD/yr.

Gender.

Diabetes mellitus.

* **Drug-related factors:**
* ESA dosing/frequency and administration route (intravenous, subcutaneous).
* Type of iron supplements (PO vs. IV) and dose and frequency of administration.
* Medications that can interfere with erythropoiesis, such as ACEI, ARB, HCV medications.
* **Iron deficiency:**
* Iron loss as a result of comorbid conditions (*e.g.*, gastrointestinal bleeding).
* Ongoing iron loss related to hemodialysis treatment and frequent blood testing.
* Iron deficiency as a result of ESA treatment–related increase in hematopoiesis.
* **Infections:**
* Overt infections such as dialysis catheter–related infections, pneumonia, and urinary tract infections.
* Latent infections such as mild peritonitis, hepatitis C, and chronic gum infection.
* **Inflammation:**
* Chronic inflammation (*e.g.*, malnutrition-inflammation complex syndrome).

**Clinical examination of:**

* Vital signs (blood pressure, pulse, temperature and respiratory rate)
* CVS regarding (heart failure, LVH, hypertension, pericardial effusion, IHD, valvular heart diseases).
* CNS regarding (cerebrovascular diseases and stroke).
* Chest examination regarding (pleural effusion, pneumonia).
* Abdominal examination regarding (ascites, peritonitis).
* Genito-urinary examination.
* Malnutrition assessment with anthropometric measures.

**Investigations:**

* Blood Hemoglobin, gm/dl.**(24**)
* Serum Creatinine mg/dl. (2**5)**
* Blood urea mg/dl. (**26)**
* Kt/V. **(27)**
* Serum Albumin, g/dl.**(28)**
* Blood Bicarbonate, mEq/L.**(29**)
* Aspartate aminotransferase, IU/L. **(30)**
* Serum total Calcium, mg/dl. **(31**)
* Serum Phosphate, mg/dl. (**32**)
* Serum Intact PTH, pg/ml**.(33**)
* Iron profile (serum iron µg/dL, ferritin level ng/ml, and transferrin saturation%)(**34)**
* HCV Antibodies **(ELISA) (35),(36)**
* Resting ECG
* Transthoracic Echocardiography
* Doppler Ultrasound

**Patients were classified into the following:**

Classification of all patients into one of three groups:

**Group A**: mean haemoglobin measurements in haemoglobin variability are less than11 gm/dL.

**Group B**: mean haemoglobin measurements in haemoglobin variability are between 11 and 13 gm/dL.

**Group C**: mean haemoglobin measurements in haemoglobin variability are more than13 gm/dL.

**Measurements of haemoglobin variability and Statistical analysis:**

Descriptive statistics are presented as mean with SD

Coefficient of hemoglobin variation: Ratio of the SD to the mean hemoglobin (**5).**

Using the first, third quartiles and the interquartile ranges.

The collected data were tabulated and analyzed using SPSS version 16 soft ware (SpssInc, Chicago, ILL Company). Categorical data were presented as number and percentages while quantitative data were expressed as mean ±standard deviation. Chi square test (X2), Fisher's exact test, z test for proportions, Anova test (f) were used as tests of significance. The accepted level of significance in this work was stated at 0.05 (P <0.05 was considered significant).

**3. Results**

**In our study we found that:**

**Group A**: Mean haemoglobin in haemoglobin variability less than 11 gm/dl.includes 41 patients of the sixty patients of the study population with percentage 68%.

80% of patients in group A who started with mean haemoglobin less than 11 gm/dl in the second month of the study remain in the same group A in the sixth month of the study.

14.5% of patients in group A who started with mean haemoglobin less than 11 gm/dl in the second month of the study crossed to group B in the sixth month of the study.

5.5% of patients in group A who started with mean haemoglobin less than 11 gm/dl in the second month of the study crossed to group C in the sixth month of the study. 73.3% of total population of the study was in group A in the sixth month of the study

**Group B**: Mean haemoglobin in haemoglobin variability between 11 and 13 gm/dl. Includes 16 patients of the sixty patients of the study population with percentage 27 %.

62.5% of patients in group B who started with mean haemoglobin between 11and 13 gm/dl in the second month of the study crossed to group A in the sixth month of the study.

18.75% of patients in group B who started with mean haemoglobin between 11and 13 gm/dl in the second month of the study remain in the same group B in the sixth month of the study.

18.75% of patients in group B who started with mean haemoglobin between 11and 13 gm/dl in the second month of the study crossed to group C in the sixth month of the study. 18.3% of total population of the study was in group B in the sixth month of the study.

**Group C**: Mean haemoglobin in haemoglobin variability more than 13gm/dl. Includes 3 patients of the sixty patients of the study population with percentage 5 %.

33% of patients in group C who started with mean haemoglobin more than 13 gm/dl in the second month of the study crossed to group A in the sixth month of the study.

67% of patients in group C who started with mean haemoglobin more than 13 gm/dl in the second month of the study crossed to group B in the sixth month of the study.

0% of patients in group C who started with mean haemoglobin more than 13 gm/dl in the second month of the study remain in the same group C in the sixth month of the study. 8.4% of total population of the study was in group C in the sixth month of the study.

**Table (1): Fluctuations in haemoglobin levels between the second and the sixth months**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | | HB 6th month | | | Total |
| Group A | Group B | Group C |
| HB  2nd month | Group A (41 patients) | 33 | 6 | 2 | 41 |
| Group B (16 patients) | 10 | 3 | 3 | 16 |
| Group C (3 patients) | 1 | 2 | 0 | 3 |
| Total | | 44 | 11 | 5 | 60 |

**Figure (1): Description of haemoglobin variability inside the same group and between the three groups of the study throughout the study time.**

The mean haemoglobin of the group A varied from one month to another but didn't cross to any other group in any month throughout the study time.

The mean haemoglobin of the group B varied from one month to another and crossed to group A in two months throughout the study time.

The mean haemoglobin of the group C varied from one month to another and crossed to group A in one month and crossed to group B in three months through the study time and overshoot in two months through the study time.

**In Group (A)**

There was significant statistical difference toward presence of HCV infection as there were 66% of patients infected with HCV virus.

Secondary hyperparathyroidism was present in group A (334.15±100.83) pg/ml.

There was highly significant statistical difference toward presence of iron deficiency as there were 95% of patients suffering from iron deficiency

There was highly significant statistical difference toward presence of cardiac diseases as there were 92.5% of patients suffering from cardiac diseases.

There was significant statistical difference toward the absence of autonomic dysfunction as there were 36.5% of patients suffering from autonomic dysfunction.

There was highly significant statistical difference toward the absence of thrombotic events as there were 2.4% of patients suffering from thrombotic events only.

There was highly significant statistical difference in the last three months of the study toward the absence of hospitalization as there were less than 5% of patients hospitalized.

There was highly significant statistical difference toward the absence of mortality as there was 2.4% mortality.

**In Group (B)**

There was significant statistical difference toward male genderas there were 62.5% males and 37.5% females.

There was significant statistical difference toward presence of HCV infection as there were 62.5% of patients infected with HCV virus. Secondary hyperparathyroidism was present in group B (383.44±125.27) pg/ml.

There was 100% presence of cardiac diseases.

There was significant statistical difference toward absence of interfering drugs with haematopoiesis as there were 37.5% of patients receiving interfering drugs with haematopoiesis**.**

There was significant statistical difference toward the absence of other infections in month one, three and four as there were less than 25% of patients suffering from infections.

There was highly significant statistical difference toward the absence of thrombotic events as there were 6.25% of patients suffering from thrombotic events.

There was highly significant statistical difference in the last three months of the study toward the absence of hospitalization as there were less than 12.5% of patients hospitalized.

**In Group (C)**

100% of the group was males

100% of the group was HCV infected

There was significant statistical difference toward presence of interfering drugs with haematopoiesis as there were 66.5% of patients receiving interfering drugs with haematopoiesis.

There was 100% presence of cardiac diseases.

There was significant statistical difference toward the absence of other infections as there were less than 33% of patients suffering from infections.

There was significant statistical difference toward the absence of weakness and fatigue as there were less than 33% of patients suffering from weakness and fatigue.

**Comparison between the three groups**

There was significant statistical difference between the three groups according to iron dose per month.

There was highly significant statistical difference between the three groups according to serum iron level, ferritin level and transferrin saturation level.

There was highly significant statistical difference between the three groups according to iron deficiency.

**Comparison between all patients of the study throughout the different quartiles**

There was statistical difference between all patients in the study throughout the different quartiles according to serum creatinine levels and this difference was statistically significant. In the first quartile (8.41±3.44 mg/dl), in the second quartile (7.08±3.07 mg/dl) and in the third quartile (6.24±2.80 mg/dl).

**Table (2): Comparison between the three groups according to gender.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Female | | Male | | Total | | X2 | p-value |
| No. | % | No. | % | No. | % |
| Group A | 19 | 46.3% | 22 | 53.7% | 41 | 100.0% | 2.6 | >0.05 |
| Group B | 6 | 37.5% | 10 | 62.5% | 16 | 100.0% |
| Group C | 0 | 0.0% | 3 | 100.0% | 3 | 100.0% |
| Total | 25 | 41.7% | 35 | 58.3% | 60 | 100.0% |

**Figure (2): Comparison between the three groups according to presence or absence of HCV infection.**

**Figure (3): Comparison between the three groups according to presence or absence of interfering drugs with haematopoiesis e.g. ACEI or ARBs.**

**Figure (4): Comparison between the three groups according to presence of cardiac diseases.**

**Table (3): Comparison between the three groups according to serum iron, ferritin levels and transferrin saturation.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | | N | Mean | ±Std. Deviation | F | *p*-value |
|
| Fe µg/dL | Group A | 41 | 40 | 20.42 | 9.1 | <0.001 |
| Group B | 16 | 70.49 | 36.90 |
| Group C | 3 | 79.44 | 49.96 |
| Ferritin ng/ml | Group A | 41 | 89.85 | 58.09 | 32.5 | <0.001 |
| Group B | 16 | 206.81 | 65.08 |
| Group C | 3 | 323.67 | 142.39 |
| Transferrin saturation% | Group A | 41 | 11.9 | 6.1 | 18.7 | <0.001 |
| Group B | 16 | 22.7 | 8.5 |
| Group C | 3 | 27.6 | 9.3 |

There was significant statistical difference between the three groups according to duration of haemodialysis

**Table (4): Comparison between the three groups according to duration of haemodialysis.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | | N | Mean | ±Std. Deviation | f | *p*-value |
|
| Duration of HD | Group A | 41 | 5.29 | 4.11 | 4.3 | <0.05 |
| Group B | 16 | 3 | 2.02 |
| Group C | 3 | 9.33 | 6.43 |

There was statistical difference between all patients in the study throughout the different quartiles according to blood Bicarbonate level levels and this difference was statistically significant in the first quartile (20.12±1.66 meq/l), in the second quartile (21.11±1.95 meq/l) and in the third quartile (21.11±1.42 meq/l).

There was statistical difference between all patients in the study throughout the different quartiles according to serum phosphorus levels and this difference was statistically significant. In the first quartile (5.54±2.63 mg/dl), in the second quartile (6.34±1.71 mg/dl) and in the third quartile (5.1±1.15 mg/dl).

**4. Discussion**

**Group A.**

There was comparison inside group A according to presence or absence of iron deficiency and there was highly significant statistical difference toward presence of iron deficiency as there were 95% of patients suffering from iron deficiency and this coincides withKalantar-Zadeh *et al.* Who said that medications that modulate hemoglobin synthesis such as iron preparations may lead to hemoglobin variability, especially at the initiation, discontinuation, and dosage titration. **(37**) And this coincides also with (Coyne) who said that reasons for hemoglobin variability include iron deficiency. **(20)**

There was comparison inside group A according to presence or absence of HCV infection and there was significant statistical difference toward presence of HCV infection as there were 66% of patients infected with HCV virus and this coincides with (Priyadarshi *et al.*, who said thatadditional reasons for hemoglobin variability include infection or inflammation.**(7)**

There was secondary hyperparathyroidism of the group A and this coincides with **(Rao et al., 1993)** who said that level of parathyroid hormone is one of the contributing factors of haemoglobin variability.

There was comparison inside group A according to presence or absence of other infections e.g., UTI, chest infections, gum and catheter related infections and this difference was statistically insignificant but there were 39% of patients suffering from infectionsand this coincides with Priyadarshi *et al.*, who said that additional reasons for hemoglobin variability include infection or inflammation.**(7)**

There was comparison inside group A according to presence or absence of cardiac diseases and there was highly significant statistical difference toward presence of cardiac diseases as there were 92.5% of patients suffering from cardiac diseases and this coincides with (Habler and Messme) who said that the myocardium may be particularly vulnerable to hemoglobin variability, as it compensates for periods of reduced oxygen delivery with increased output and myocardial cell growth.**(38)** And coincides also with Parfrey *et al.*, who said that Accelerated left ventricular dysfunction and hypertrophy may be associated with hemoglobin variability.**(23)**

There was comparison inside group A according to presence or absence of weakness and fatigue and this difference was statistically insignificant but there were 51% of patients suffering from weakness and fatigue and this coincides with (Macdougall) who said thathemoglobin variability may be associated with fatigue and weakness. **(18)**

**Group B**

There was comparison inside group B according to gender and there was significant statistical difference toward male genderas there were 62.5% males and 37.5% females.

There was comparison inside group B according to presence or absence of HCV infection and there was significant statistical difference toward presence of HCV infection as there were 62.5% of patients infected with HCV virus and this coincides with (Priyadarshi *et al.*) who said that additional reasons for hemoglobin variability include infection or inflammation **(7).**

There was secondary hyperparathyroidism of the group and this coincides with **(Rao et al., 1993)** who said that level of parathyroid hormone is one of the contributing factors of haemoglobin variability.

There was comparison inside group B according to presence or absence of cardiac diseases and there was 100% presence of cardiac diseases.

There was comparison inside group B according to presence or absence of autonomic dysfunction and there was 50% presence of autonomic dysfunctionand this coincides with(Romero et al) who said thatthe autonomic nervous system may also be vulnerable to hemoglobin variability, as autonomic dysfunction has been observed in other conditions that predispose patients to fluctuating hemoglobin levels, such as sickle cell anemia In this population, autonomic dysfunction has been implicated as a putative risk factor for sudden death**.(39).**

**Group C**

There was comparison inside group C according to gender and 100% of the group was males.

There was comparison inside group C according to presence or absence of HCV infection and 100% of the group was HCV infectedand this coincides with (Priyadarshi *et al.*) who said thatadditional reasons for hemoglobin variability include infection or inflammation.**(7)**

There was comparison inside group C according to presence or absence of interfering drugs with haematopoiesis and there was significant statistical difference toward presence of interfering drugs with haematopoiesis as there were 66.5% of patients receiving interfering drugs with haematopoiesis and this coincides with (Ishani *et al.*) who said that cardiovascular medications such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers that are commonly used in this patient population, may lead to hemoglobin variability, especially at the initiation, discontinuation, and dosage titration. **(40**)

There was comparison inside group C according to presence or absence of cardiac diseases and there was 100% presence of cardiac diseasesand this coincides with (Habler and Messme) who said that the myocardium may be particularly vulnerable to hemoglobin variability, as it compensates for periods of reduced oxygen delivery with increased output and myocardial cell growth. **(38)** And coincides also with (Parfrey *et al.*) who said that Accelerated left ventricular dysfunction and hypertrophy may be associated with hemoglobin variability**.(23)**

**The Three Groups**

There was statistical difference between the three groups according to duration of haemodialysis and this difference was statistically significant.

There was statistical difference between the three groups according to mean ESA dose per month and this difference was statistically insignificant. Darbiboetin was used subcutaneously every week according to individualized anemia management protocol which may make it out of the factors causing Hb variability here and this coincides with (Besarab *et al.*) who said thatlonger dosing intervals may lead to less variability in hemoglobin levels over time by producing fewer peaks and troughs and thereby requiring fewer dosage adjustments). **(41)**

There was statistical difference between the three groups according to mean iron dose per month and this difference was statistically significant and this coincides with (Kalantar-Zadeh *et al.*). Who said that medications that modulate hemoglobin synthesis such as iron preparations may lead to hemoglobin variability, especially at the initiation, discontinuation, and dosage titration. **(37)**

There was statistical difference between the three groups according to serum iron, ferritin levels and transferrin saturation and this difference was statistically highly significant and this coincides with that (Gotloib *et al.*) who said that additional reasons for hemoglobin variability include alteration in iron stores**.(6)** And iron deficiency(Coyne) **(20).**

There was statistical difference between the three groups according to presence of iron deficiency and this difference was statistically highly significant and this coincides with (Kalantar-Zadeh *et al.*). Who said that medications that modulate hemoglobin synthesis such as iron preparations may lead to hemoglobin variability, especially at the initiation, discontinuation, and dosage titration. (**37).** And this coincides also with (Coyne) who said that reasons for hemoglobin variability include iron deficiency.**(20)**

**All Patients throughout Different Quartiles**

There was statistical difference between all patients in the study throughout the different quartiles according to serum creatinine levels, blood bicarbonate levels and serum phosphorus levels and this difference was statistically significant.

**4. Conclusion**

We have found haemoglobin variability to be a frequent finding in haemodialysis patients treated with rHuEPO. Iron treatment, iron deficiency, secondary hyperparathyroidism, HCV virus infection, interfering drugs with haematopoiesis e.g., ACEI or ARBs and male gender were significant contributing factors for haemoglobin variability. Other infections e.g., UTI, chest infections, gum and catheter related infections might play a role as a contributing factor for haemoglobin variability. Cardiac diseases and were significant consequences of haemoglobin variability. Weakness, fatigue and autonomic dysfunction might be consequences of haemoglobin variability.

**Recommendations**

We need to do every effort to minimize haemoglobin variability in haemodialysis patients treated with rHuEPO by reducing incidence of contributing factors of haemoglobin variability by: Applying smart anemia management protocol or individualized anemia management protocol with avoidance of drastic changes in ESA dose and better management of iron status, proper management of hyperparathyroidism, prophylaxis and treatment of HCV infection and other infections and Reducing the use of drugs that interfere with haemtopiesis unless indicated. We need a study with large sample size, multicenter design and longer duration to make the results be easily generalizable.

**References**

1. Brimble KS, Clase CM: Hemoglobin variability in dialysis patients. J Am Soc Nephrol 18: 2218–2220, 2007.
2. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B: Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease.Clin J Am Soc Nephrol 1: 1211–1215, 2006.
3. Maraldi C, Ble A, Zuliani G, Guralnik JM, Mussi C, Fellin R, Volpato S: Association between anemia and physical disability in older patients: Role of comorbidity. Aging ClinExp Res 18: 485–492, 2006.
4. Ofsthun NJ, Lazarus JM: Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients. Blood Purif 25: 31–35, 2007.
5. Ebben JP, Gilbertson DT, Foley RN, Collins AJ: Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol1: 1205–1210, 2006.
6. Gotloib L, Silverberg D, Fudin R, Shostak A: Iron deficiency is a common cause of anemiain chronic kidney disease and can often be corrected with intravenous iron. J Nephrol19: 161–167, 2006.
7. Priyadarshi A, Shapiro JI: Erythropoietin resistance in the treatment of the anemia of chronic renal failure. Semin Dial 19: 273–278, 2006.
8. Yabana M, Ikeda Y, Kihara M, Kurita K, Toya Y, Tamura K, Takagi N, Onishi T, Umemura S: Good response of endogenous erythropoietin to blood loss in persistently improving renal anemia after discontinuation of erythropoietin treatment. Nephron 81: 111–112, 1999.
9. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med; 334:420–425. 1996.
10. Pyo HJ, Kwon YJ, Wee KS, Kwon SY, Lee CH, Kim S, Lee JS, Cho SH, Cha CW: An outbreak of Heinz body positive hemolytic anemia in chronic hemodialysis patients. Korean J Intern Med 8: 93–98, 1993.
11. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE: Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 69: 560–564, 2006.
12. Rao DS, Shih MS, Mohini R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328: 171–175, 1993.
13. Witte KK, Desilva R, Chattopadhyay S, Ghosh J, Cleland JG, Clark AL: Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J 147: 924–930, 2004.
14. Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD: Appetite and inflammation, nutrition, anemia and clinical outcome in hemodialysis patients. Am J Clin Nutr 80: 299–307, 2004.
15. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD: Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42: 761–773, 2003.
16. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB: Hemoglobin variabilityin epoetin-treated hemodialysis patients. Kidney Int 64: 1514–1521, 2003.
17. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ: Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 3: 133–138, 2008.
18. Macdougall IC: Quality of life and anemia: the nephrology experience. Semin Oncol 25: 39–42, 1998.
19. Chen J, Gul A, Sarnak MJ: Management of intradialytic hypertension: The ongoing challenge. Semin Dial 19: 141–145, 2006.
20. Coyne D: Challenging the boundaries of anemia management: A balanced approach to i.v. iron and EPO therapy. Kidney Int Suppl S1–S3, 2006.
21. Dahl NV, Henry DH, Coyne DW: Thrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role? Semin Dial 21: 210–211, 2008.
22. Kooistra MP, van Es A, Marx JJ, Hertsig ML, Struyvenberg A: Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrol Dial Transplant 9: 1115–1120, 1994.
23. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D: Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16: 2180–2189, 2005.
24. Mohandas N, Kim YR, Tycko DH, Orlik J, Wyatt J,Groner W. Accurate and independent measurement of volume and haemoglobin concentration of individual red cells by laser light scattering. Blood,68:506-13.1986.
25. Endres DB & Rude RK: Mineral and bone metabolism. In: Tietz textbook of clinical chemistry. Burtis CA, Ashwood ER, editors. 3rd ed. Pheladelphia: W.B Saunders Company, P. 1395-1457. 1999.
26. Burtis CA &AshwoodER :editors. Tietz textbook of clinical chemistry. 3rd ed. Pheladelphia: W.B Saunders Company. P. 1838-18561999.
27. Daugirdas Formula) for kt/v calculation.
28. Johnson AM, Rohlfs EM & Silverman LM Proteins. In: Tietz textbook of clinical chemistry. Burtis CA, Ashwood ER, editors. 3rd ed. Pheladelphia: W.B Saunders Company, P. 617-721. 1999.
29. Hall NP, Cornelius MJ, Keys AJ. The enzymatic determination of bicarbonate and CO2 in reagents and buffer solutions. Anal Biochem,132:152-7.1983.
30. Schuman G, Bonora R & Ceriotti F et al: IFCC primary reference procedures for the management of catalytic activity concentrations of enzymes at 37°C. Part 5. Referance procedure for the measurement of catalytic concentration of Alanine Aminotransferase Clin Chem Lab Med;40(7):725-788. 2002.
31. Robertson WG, Marshall RW. Calcium measurements in serum and plasma: total and ionized. CRC Crit Rev Clin Lab Sci,11:271-304.1979.
32. Atkinson A, Gatenby AD, Lowe AG. The determination of inorganic orthphosphate in biological systems. Biochem Biophys Acta, 320:195-204.1973.
33. Endres DB. Which parathyrin assay is really best for clinic use? Clin Chem, 37:1466-7.1991.
34. Rice EW, Fenner HE. Study of the ICSH proposed reference method for serum iron assay: Obtaining optically clear filtrates and substitution of ferrozine.Clin Chim Acta,53:391-3.1974.
35. Alter M, Kuhnert W, Finelli L. Guidelines for laboratory testing and results reporting of antibody to hepatitis C virus.MMWR Morb Mortal WKLY Rep,52:1-15.2003.
36. Dufour DR, Talastas M, Fernandez, Harris B, Strader D, Seeff L. Low positive anti hepatitis C virus enzyme immunoassay results: An important predictor of low likelihood of hepatitis C infection. Clin Chem,49:479-86.2003.
37. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG: Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16: 3070–3080, 2005.
38. Habler OP, Messmer KF: The physiology of oxygen transport. Transfus Sci 18: 425–435, 1997.
39. Romero Mestre JC, Hernandez A, Agramonte O, Hernandez P: Cardiovascular autonomic dysfunction in sickle cell anemia: A possible risk factor for sudden death? Clin Auton Res 7: 121–125, 1997.
40. Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S, Herzog CA: Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 45: 391–399, 2005.
41. Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U: Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: A 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Clin Ther 29: 626–639, 2007.

9/28/2015